Navigation Links
Alnylam Reports Results of Human Experimental Infection Model with,Respiratory Syncytial Virus

udy to assess the safety and tolerability of intranasally delivered ALN-RSV01 versus placebo, administered to healthy adult volunteers experimentally inoculated with the RSV virus. The study, expected to enroll approximately 90 subjects, aims to determine the safety and anti-viral activity of ALN-RSV01 as measured toward clinical symptoms of RSV infection and RSV infection rate based on measures of viral load.

About Respiratory Syncytial Virus (RSV)

RSV is a highly contagious virus that causes infections in both the upper and lower respiratory tract. RSV infects nearly every child at least once by the age of two years and is a leading cause of hospitalization due to respiratory infection in children and in people with compromised immune systems, and others. RSV infection typically results in cold-like symptoms but can lead to more serious respiratory illnesses such as croup, pneumonia, bronchiolitis, and in extreme cases, death. RSV infection in the pediatric population accounts for more than 125,000 hospitalizations per year in the U.S. In addition, RSV infection in infants has been linked to the development of childhood asthma. As a result, there is a significant need for novel therapeutics to treat patients who become infected with RSV.

About RNA Interference (RNAi)

RNA interference (or RNAi) is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. The discovery of RNAi has been widely acknowledged as a major breakthrough in biology, and the technology was recognized for its potential broad impact in medicine with the award of the 2006 Nobel Prize for Physiology or Medicine. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi has accelerated the understanding of these genes and their related pathways. Additionally, RNAi could provide a new way to treat a wide range of human diseases. RNAi is induced by small
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
2. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:8/22/2014)...  - MediaLINC unlocks the real ... general availability of MediaLINC - its innovative ... education, entertainment and clinical content direct to standard HD ... " Lincor has already been phenomenally ... bedside smart devices, " comments Dan Byrne , ...
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - SQI ... that develops and commercializes proprietary technologies and products ... has entered into a Master Service Agreement to ... DNA-based pathogen detection assays. During the initial phase ... deliver an automated working prototype of one of ...
(Date:8/21/2014)... Memorial Hermann Health System and The University of ... partnership to provide a new level of specialized breast screening ... greater Houston area. Starting ... of professional breast radiology services for five of Memorial Hermann,s ... The Woodlands , Northeast, Southwest and Sugar ...
Breaking Medicine Technology:Lincor Unveils Next Generation TV-based Patient Engagement Solution 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4
... Feb. 16, 2012  OnSiteRx®, Inc. ( http://www.onsiterx.com ), parent ... Covenant Health Network, announces today that they have successfully ... in a long-term care facility in the state of ... can increase patient safety and lower medication cost," states ...
... 16, 2012  Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX ) ... the fourth quarter and year end 2011 on Thursday, February ... Idenix management will host a conference call at 4:30 p.m. ... financial results for the fourth quarter and year end 2011 ...
Cached Medicine Technology:OnSiteRx® Launches First for Arizona: Automated Drug Dispensing in Nursing Home 2
(Date:8/22/2014)... August 22, 2014 Mueller Sports Medicine ... Fasciitis, an exciting new product that provides non-drug instant ... stay active while you heal. The package includes 7 ... a new technology – it is not kinesiology tape. ... FasciaDerm® PFTape™ System for Plantar Fasciitis is a ...
(Date:8/22/2014)... The improved access to antiretroviral drugs ... developing world, has led to the decline in the ... due to AIDS globally. However, despite the fact that ... patients becoming affected by the virus is on the ... all related organisations and stakeholders, by 2015, significant investments ...
(Date:8/22/2014)... -- Back-to-school time provides an opportunity for parents to ... schedules, an expert suggests. "Forget New Year,s resolutions; ... be the start of a new fitness and exercise ... at the University of the Sciences in Philadelphia, said ... activities likely to build up, "it,s important for mom ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Dayton Children's Hospital ... tower as part of a $141 million campus renewal. ... care tower were unveiled to the public. , The ... plan that will create a campus that meets the needs ... These new care spaces will embody Dayton Children’s unique patient ...
(Date:8/22/2014)... Renal artery stenting to open blockages in ... historically been excluded from modern clinical trials, according ... in Catheterization and Cardiovascular Interventions today ... (SCAI). , University Hospitals Case Medical Center,s Sahil ... Professor of Medicine, Case Western Reserve University School ...
Breaking Medicine News(10 mins):Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3Health News:With Kids in School, Parents Can Work Out 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 3
... The largest exhibition of simulation technology ever held, will feature ... surgery to epidemic prediction and management on December 1-4 at ... ... Orlando, FL (Vocus) November 20, 2008 ...
... National Capital Philanthropy Day Awards , ... ... Lintott, chairman of the board of the Children,s Hospital Foundation ... Volunteer" at the National Capital Philanthropy Day Awards presented by ...
... Performance Materials (OPM) has received ISO 9001:2000 and ISO 13485:2003 certification ... established and applies a quality system for contract moulding of PEKK ... polymer shapes. The Certificate was issued by TUV USA Inc. and ... ...
... premier educational gathering of the world,s leading laser experts hosted by ... ... Wausau, WI (PRWEB) November 20, 2008 -- The American Society ... National Harbor, Md., April 1 - 5, 2009     , , ...
... 20 , - Sharp Growth in Sales and ... , - Sales in the Third Quarter Grew 36.9% to ... M, - Operating Profit Grew by 79.6% to US$ 15 M, ... Net Profit Grew by 60.7% to US$ 9.4 M, - Cash Flow ...
... and Inexcusable" , , 25,000 young ... , UNICEF USA Appeals for Public ... , NEW YORK, Nov. 20 ... shameful and unnecessary, the U.S. Fund for UNICEF today marked Universal ...
Cached Medicine News:Health News:Medical Technology to be Highlighted at World's Largest Simulation Exhibition 2Health News:James W. Lintott Named Outstanding Fundraising Volunteer Of The Year 2Health News:Oxford Performance Materials Received ISO 13485 and ISO 9001 Certification 2Health News:Announcing a Monumental Sharing of Laser Innovation: The American Society for Laser Medicine and Surgery (ASLMS) Holds 29th Annual Conference in National Harbor, Md., April 1 - 5, 2009 2Health News:Frutarom Continues to Implement its Rapid Growth Strategy 2Health News:Frutarom Continues to Implement its Rapid Growth Strategy 3Health News:Frutarom Continues to Implement its Rapid Growth Strategy 4Health News:Frutarom Continues to Implement its Rapid Growth Strategy 5Health News:Important Message for 2008 Universal Children's Day 2Health News:Important Message for 2008 Universal Children's Day 3
... stabilized hyaluronic acid-based dermal filler and ... the U.S. market. It is indicated ... facial wrinkles and folds (such as ... under the skins surface to replenish ...
... Response is a whole blood ... be used at the point-of-care. ... screen and data management features, ... options. QC and operator lockout ...
... clinically proven aminophylline directly to the area ... reduction with the aminophylline containing cream has ... increase in the firmness of the thighs. ... skin where it causes the body fat ...
... is a unique, non-invasive way of ... of cellulite and improving overall skin ... was used to rehabilitate scars, burns ... surprising side-affect was discovered - the ...
Medicine Products: